GMP Certified / Meloxicam Injection 15mg/1.5ml

• Quality Standard: Bp, USP
• Ctd Dossier: Ready
• Documentation: Copp, COA
• Factory Certification: GMP
• Transport Package: Carton
• Specification: 15mg/1.5ml
• Model NO.: injection
• Trademark: Sinolead
• Origin: China
• Production Capacity: 100, 000, 000 Per Year

Product Description

Product Description

Generic Name	Meloxicam Injection
Strength	15mg/1.5ml
Packing	5 amps/box
Origin	China

Value-added services:
 Packaging design by our team
 Registration service by our team
 Registration dossier available by our team
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Product name:
Meloxicam Injection

Character:
This product is almost colorless clear liquid.

Indications:
- Rheumatoid arthritis:
- Painful osteoarthritis (joint disease, degenerative joint disease) :
- Ankylosing spondylitis.

Adverse reactions:
The adverse reactions listed below may be related to the administration of this product. However, the frequency of occurrence is based on the results of clinical trials, regardless of whether there is a causal relationship with the administration of this product. The information is based on a clinical trial of 3,750 patients who received oral Mobicol tablets or capsules 7.5mg or 15mg per day for up to 18 months (average course of treatment was 127 days), and 254 patients who received intramuscular Mobicol for up to 7 days.
Adverse reactions that may be caused by the use of the oral dosage form Mobican in the market are also listed.
It is difficult to quantify the incidence of these rare adverse reactions. The frequency of adverse reactions was estimated to be less than 0.1%.
Digestive system:
Occurrence frequency is greater than 1%; Indigestion, nausea, vomiting, abdominal pain, constipation, flatulence, diarrhea.
The frequency is between 0.1% and 1% : temporary abnormalities in indicators of liver function (such as elevated aminotransferase or bilirubin), heating, esophagitis, gastroduodenal ulcers, hidden or gross gastrointestinal bleeding.
Gastrointestinal perforation occurs less than 0.1% of the time. Colitis, hepatitis, gastritis.
Gastrointestinal bleeding, ulceration or perforation can be fatal.
Blood system:
Frequency greater than 1% : anemia.
The frequency is between 0.1% and 1% : disturbance of the blood count, including changes in the white blood cell count, leukopenia, and thrombocytopenia. Concurrent administration of potentially myelotoxic drugs, especially methotrexate, is a predisposition factor for the development of hemocytopenia.
Skin:
Frequency greater than 1%: pruritus, rash.
Frequency between 0.1% and 1% : stomatitis, urticaria.
Frequency less than 0.1% : photosensitive. In a very small number of patients, bullous reaction, erythema multiforme, Stevens-Johnson combination sign, and toxic epidermal lytic necrosis may occur.
Respiratory system:
Frequency less than 0.1% : Asthma attacks can occur in some patients who are allergic to aspirin or other NSAIDs.
Central nervous System:
Frequency greater than 1%: dizziness, headache.
Frequency between 0.1% and 1% : vertigo, tinnitus. Lethargy.
The frequency is lower than O.l% confusion and disorientation, mood changes.
Cardiovascular system:
Frequency greater than 1% : edema.
The frequency is between O.l% and 1% : increased blood pressure, palpitations, flushed face.
Genitourinary system:
Frequency between 0.1% and 1% : Abnormal indicators of kidney function (elevated serum creatinine and/or serum urea).
Frequency less than 0.1% : acute renal failure.
Visual Disorders:
Frequency less than 0.1% : conjunctivitis. Visual impairment, including blurred vision.
Hypersensitivity:
Frequency less than 0.1% : angioedema and rapid hypersensitivity, including anaphylaxis.
Application site diseases:
Frequency greater than 1% : swelling at the injection site.
Frequency between 0.1% and 1% : pain at the injection site.

Storage:
Keep out of light and tightly sealed.